AngioDynamics Receives FDA IDE Approval For RELIEF Feasibility Study Evaluating NanoKnife IRE Platform As Minimally Invasive Treatment For Benign Prostatic Hyperplasia CI Jun. 17 AngioDynamics Secures ...
AngioDynamics expects full-year results to range from a loss of 29 cents per share to a loss of 24 cents per share, with revenue in the range of $336 million to $341 million. AngioDynamics shares have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results